[S02DA03, antipyrine, The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Ticagrelor.]
[G03XB02, ulipristal, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Ulipristal.]
[B01AD01, streptokinase, The risk or severity of bleeding can be increased when Ticagrelor is combined with Streptokinase.]
[L01AD04, streptozocin, The risk or severity of bleeding can be increased when Ticagrelor is combined with Streptozocin.]
[J01EC01, sulfamethoxazole, The metabolism of Sulfamethoxazole can be decreased when combined with Ticagrelor.]
[M04AB02, sulfinpyrazone, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Ticagrelor.]
[M01AB02, sulindac, The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Ticagrelor.]
[A10BB04, glibornuride, The metabolism of Glibornuride can be decreased when combined with Ticagrelor.]
[M01AX04, apazone, The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Ticagrelor.]
[L01BB02, mercaptopurine, The risk or severity of bleeding can be increased when Ticagrelor is combined with Mercaptopurine.]
[L02BA01, tamoxifen, The risk or severity of bleeding can be increased when Tamoxifen is combined with Ticagrelor.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Ticagrelor.]
[B01AE07, dabigatran etexilate, Ticagrelor may increase the anticoagulant activities of Dabigatran etexilate.]
[G03BA03, testosterone, Testosterone may increase the anticoagulant activities of Ticagrelor.]
[J01DI02, ceftaroline fosamil, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Ceftaroline fosamil.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Ticagrelor.]
[N04BC07, apomorphine, The metabolism of Ticagrelor can be decreased when combined with Apomorphine.]
[L04AX02, thalidomide, The metabolism of Ticagrelor can be increased when combined with Thalidomide.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Ticagrelor.]
[L01XX41, eribulin, The risk or severity of bleeding can be increased when Ticagrelor is combined with Eribulin.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be decreased when combined with Ticagrelor.]
[L01BB03, thioguanine, The risk or severity of bleeding can be increased when Ticagrelor is combined with Tioguanine.]
[B01AC05, ticlopidine, The risk or severity of bleeding can be increased when Ticlopidine is combined with Ticagrelor.]
[N02AX01, tilidine, Tilidine can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A10BB05, tolazamide, The metabolism of Tolazamide can be decreased when combined with Ticagrelor.]
[V04CA01, tolbutamide, The metabolism of Tolbutamide can be decreased when combined with Ticagrelor.]
[M02AA21, tolmetin, The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Ticagrelor.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Ticagrelor.]
[N06AF04, tranylcypromine, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Ticagrelor.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Trapidil is combined with Ticagrelor.]
[N06AX05, trazodone, The risk or severity of bleeding can be increased when Trazodone is combined with Ticagrelor.]
[L01XF01, tretinoin, The metabolism of Ticagrelor can be decreased when combined with Tretinoin.]
[S01BA05, triamcinolone, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Triamcinolone.]
[N05CD05, triazolam, The metabolism of Ticagrelor can be decreased when combined with Triazolam.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Trichlormethiazide.]
[R03BA07, mometasone, The metabolism of Ticagrelor can be increased when combined with Mometasone.]
[N03AC02, trimethadione, The metabolism of Trimethadione can be decreased when combined with Ticagrelor.]
[J01EA01, trimethoprim, The metabolism of Trimethoprim can be decreased when combined with Ticagrelor.]
[N06AA06, trimipramine, The serum concentration of Trimipramine can be increased when it is combined with Ticagrelor.]
[J01FA08, troleandomycin, The metabolism of Ticagrelor can be decreased when combined with Troleandomycin.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Ticagrelor.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be decreased when combined with Ticagrelor.]
[A10BH05, linagliptin, The metabolism of Ticagrelor can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Ticagrelor can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Ticagrelor can be decreased when combined with Telaprevir.]
[B01AD04, urokinase, Urokinase may increase the anticoagulant activities of Ticagrelor.]
[B01AF01, rivaroxaban, Ticagrelor may increase the anticoagulant activities of Rivaroxaban.]
[R03AC18, indacaterol, The serum concentration of Indacaterol can be increased when it is combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Ticagrelor can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Ticagrelor can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The serum concentration of Vinblastine can be increased when it is combined with Ticagrelor.]
[L01CA02, vincristine, The excretion of Vincristine can be decreased when combined with Ticagrelor.]
[L01CA03, vindesine, The metabolism of Vindesine can be decreased when combined with Ticagrelor.]
[A11HA03, vitamin E, Vitamin E may increase the antiplatelet activities of Ticagrelor.]
[B01AA03, warfarin, The serum concentration of Warfarin can be increased when it is combined with Ticagrelor.]
[S01AA13, fusidic acid, The metabolism of Ticagrelor can be decreased when combined with Fusidic acid.]
[J05AF01, zidovudine, The risk or severity of bleeding can be increased when Ticagrelor is combined with Zidovudine.]
[N05AF05, zuclopenthixol, The metabolism of Zuclopenthixol can be decreased when combined with Ticagrelor.]
[J05AE02, indinavir, The metabolism of Ticagrelor can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The serum concentration of Ticagrelor can be increased when it is combined with Vemurafenib.]
[L01FX05, brentuximab vedotin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Ticagrelor.]
[L01ED01, crizotinib, The serum concentration of Crizotinib can be increased when it is combined with Ticagrelor.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Ticagrelor is combined with Lepirudin.]
[R03DC01, zafirlukast, The metabolism of Zafirlukast can be decreased when combined with Ticagrelor.]
[N05AE04, ziprasidone, The metabolism of Ticagrelor can be decreased when combined with Ziprasidone.]
[G03AC10, drospirenone, The risk or severity of adverse effects can be increased when Drospirenone is combined with Ticagrelor.]
[L04AA34, alemtuzumab, The risk or severity of bleeding can be increased when Ticagrelor is combined with Alemtuzumab.]
[N02BA01, aspirin, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be decreased when combined with Ticagrelor.]
[G04BD07, tolterodine, The metabolism of Tolterodine can be decreased when combined with Ticagrelor.]
[L03AB11, peginterferon alfa-2a, The risk or severity of bleeding can be increased when Ticagrelor is combined with Peginterferon alfa-2a.]
[L01FA01, rituximab, The risk or severity of bleeding can be increased when Ticagrelor is combined with Rituximab.]
[J02AC03, voriconazole, The metabolism of Ticagrelor can be decreased when combined with Voriconazole.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Ticagrelor.]
[L01EK01, axitinib, The serum concentration of Axitinib can be increased when it is combined with Ticagrelor.]
[R07AX02, ivacaftor, The serum concentration of Ticagrelor can be increased when it is combined with Ivacaftor.]
[H02AB11, prednylidene, The metabolism of Ticagrelor can be increased when combined with Prednylidene.]
[L01BC07, azacitidine, The risk or severity of bleeding can be increased when Ticagrelor is combined with Azacitidine.]
[L01BC05, gemcitabine, The serum concentration of Gemcitabine can be increased when it is combined with Ticagrelor.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Ticagrelor.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of bleeding can be increased when Ticagrelor is combined with Gemtuzumab ozogamicin.]
[G04BD12, mirabegron, The serum concentration of Mirabegron can be increased when it is combined with Ticagrelor.]
[L01XG02, carfilzomib, The serum concentration of Carfilzomib can be increased when it is combined with Ticagrelor.]
[V03AX03, cobicistat, The metabolism of Ticagrelor can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Ticagrelor can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The metabolism of Ticagrelor can be increased when combined with Enzalutamide.]
[L01EA04, bosutinib, The serum concentration of Bosutinib can be increased when it is combined with Ticagrelor.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Defibrotide is combined with Ticagrelor.]
[L01EX05, regorafenib, The serum concentration of Regorafenib can be increased when it is combined with Ticagrelor.]
[J05AE04, nelfinavir, The metabolism of Ticagrelor can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The serum concentration of Bendamustine can be increased when it is combined with Ticagrelor.]
[N04BD02, rasagiline, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Ticagrelor.]
[C08CA13, lercanidipine, The metabolism of Ticagrelor can be decreased when combined with Lercanidipine.]
[N06DA02, donepezil, The metabolism of Donepezil can be decreased when combined with Ticagrelor.]
[N03AX22, perampanel, The metabolism of Perampanel can be decreased when combined with Ticagrelor.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Ticagrelor.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Ticagrelor.]
[G04BE03, sildenafil, The risk or severity of hemorrhage can be increased when Ticagrelor is combined with Sildenafil.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Ticagrelor.]
[B01AF02, apixaban, Apixaban may increase the anticoagulant activities of Ticagrelor.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be decreased when combined with Ticagrelor.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Bendroflumethiazide.]
[L04AX06, pomalidomide, The serum concentration of Pomalidomide can be increased when it is combined with Ticagrelor.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Ticagrelor.]
[N02BA10, benorilate, The risk or severity of bleeding and hemorrhage can be increased when Benorilate is combined with Ticagrelor.]
[A10BK02, canagliflozin, The serum concentration of Canagliflozin can be increased when it is combined with Ticagrelor.]
[A06AX06, tegaserod, The serum concentration of Tegaserod can be increased when it is combined with Ticagrelor.]
[M01AH01, celecoxib, The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Ticagrelor.]
[L04AA18, everolimus, The serum concentration of Everolimus can be increased when it is combined with Ticagrelor.]
[L01EC02, dabrafenib, The serum concentration of Ticagrelor can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of bleeding and hemorrhage can be increased when Benzydamine is combined with Ticagrelor.]
[L01EB03, afatinib, The serum concentration of Afatinib can be increased when it is combined with Ticagrelor.]
[N06AX28, levomilnacipran, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Ticagrelor.]
[J05AJ03, dolutegravir, The serum concentration of Dolutegravir can be increased when it is combined with Ticagrelor.]
[C02KX05, riociguat, The serum concentration of Riociguat can be increased when it is combined with Ticagrelor.]
[A05AA03, cholic acid, The risk or severity of adverse effects can be increased when Ticagrelor is combined with Cholic Acid.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Ticagrelor.]
[N06AX26, vortioxetine, The risk or severity of bleeding can be increased when Vortioxetine is combined with Ticagrelor.]
[G03AC08, etonogestrel, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Etonogestrel.]
[J05AP05, simeprevir, The metabolism of Ticagrelor can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, The serum concentration of Sofosbuvir can be increased when it is combined with Ticagrelor.]
[A10BK01, dapagliflozin, The metabolism of Dapagliflozin can be decreased when combined with Ticagrelor.]
[N05CH03, tasimelteon, The metabolism of Tasimelteon can be decreased when combined with Ticagrelor.]
[A16AA07, metreleptin, The metabolism of Ticagrelor can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Ticagrelor can be increased when combined with Apremilast.]
[S03BA03, betamethasone, The metabolism of Ticagrelor can be increased when combined with Betamethasone.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Ticagrelor is combined with Argatroban.]
[L04AC11, siltuximab, The metabolism of Ticagrelor can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The serum concentration of Ceritinib can be increased when it is combined with Ticagrelor.]
[B01AC26, vorapaxar, The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Ticagrelor.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be increased when it is combined with Ticagrelor.]
[L01XH04, belinostat, The serum concentration of Belinostat can be increased when it is combined with Ticagrelor.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be decreased when combined with Ticagrelor.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be decreased when combined with Ticagrelor.]
[L03AB13, peginterferon beta-1a, The risk or severity of bleeding can be increased when Ticagrelor is combined with Peginterferon beta-1a.]
[N05CM19, suvorexant, The serum concentration of Ticagrelor can be increased when it is combined with Suvorexant.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Ticagrelor.]
[A06AH03, naloxegol, The serum concentration of Naloxegol can be increased when it is combined with Ticagrelor.]
[L01BC08, decitabine, The risk or severity of bleeding can be increased when Ticagrelor is combined with Decitabine.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Ticagrelor.]
[L01EX09, nintedanib, The risk or severity of bleeding can be increased when Nintedanib is combined with Ticagrelor.]
[L01FX07, blinatumomab, The risk or severity of bleeding can be increased when Ticagrelor is combined with Blinatumomab.]
[J05AP09, dasabuvir, The serum concentration of Dasabuvir can be increased when it is combined with Ticagrelor.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Ticagrelor.]
[B01AA01, dicumarol, The risk or severity of bleeding can be increased when Ticagrelor is combined with Dicoumarol.]
[B01AF03, edoxaban, The risk or severity of bleeding can be increased when Edoxaban is combined with Ticagrelor.]
[L04AC10, secukinumab, The metabolism of Ticagrelor can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be decreased when combined with Ticagrelor.]
[L01EX08, lenvatinib, The serum concentration of Lenvatinib can be increased when it is combined with Ticagrelor.]
[L01XH03, panobinostat, The serum concentration of Panobinostat can be increased when it is combined with Ticagrelor.]
[J05AP07, daclatasvir, The serum concentration of Ticagrelor can be increased when it is combined with Daclatasvir.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Ticagrelor is combined with Tioclomarol.]
[J05AP06, asunaprevir, The serum concentration of Ticagrelor can be increased when it is combined with Asunaprevir.]
[A07DA06, eluxadoline, Eluxadoline can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Cangrelor is combined with Ticagrelor.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be decreased when combined with Ticagrelor.]
[A04AD14, rolapitant, The serum concentration of Ticagrelor can be increased when it is combined with Rolapitant.]
[G02CX02, flibanserin, The serum concentration of Ticagrelor can be increased when it is combined with Flibanserin.]
[M02AA25, aceclofenac, The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Ticagrelor.]
[M01AB11, acemetacin, The risk or severity of bleeding and hemorrhage can be increased when Ticagrelor is combined with Acemetacin.]
[A02BC03, lansoprazole, The metabolism of Lansoprazole can be decreased when combined with Ticagrelor.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Ticagrelor.]
[J02AC05, isavuconazole, The serum concentration of Ticagrelor can be increased when it is combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Osimertinib can be increased when it is combined with Ticagrelor.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ticagrelor.]
[L01EE02, cobimetinib, The serum concentration of Cobimetinib can be increased when it is combined with Ticagrelor.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be decreased when combined with Ticagrelor.]
[V03AB35, sugammadex, The risk or severity of bleeding and hemorrhage can be increased when Ticagrelor is combined with Sugammadex.]
[L01ED03, alectinib, The metabolism of Alectinib can be decreased when combined with Ticagrelor.]
[B01AC27, selexipag, The serum concentration of Selexipag can be increased when it is combined with Ticagrelor.]
[A10BB31, acetohexamide, The metabolism of Acetohexamide can be decreased when combined with Ticagrelor.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Ticagrelor.]
[M04AB05, lesinurad, The metabolism of Lesinurad can be decreased when combined with Ticagrelor.]
[J05AP10, elbasvir, The serum concentration of Elbasvir can be increased when it is combined with Ticagrelor.]
[J05AP11, grazoprevir, The serum concentration of Grazoprevir can be increased when it is combined with Ticagrelor.]
[M01AE16, alminoprofen, The risk or severity of bleeding and hemorrhage can be increased when Alminoprofen is combined with Ticagrelor.]
[N02BA02, aloxiprin, The risk or severity of bleeding can be increased when Aloxiprin is combined with Ticagrelor.]
[N03AX23, brivaracetam, The metabolism of Brivaracetam can be decreased when combined with Ticagrelor.]
[L01XX52, venetoclax, The serum concentration of Venetoclax can be increased when it is combined with Ticagrelor.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be decreased when combined with Ticagrelor.]
[A05AA04, obeticholic acid, The risk or severity of adverse effects can be increased when Ticagrelor is combined with Obeticholic acid.]
[N07BC01, buprenorphine, Buprenorphine can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05BE01, buspirone, The metabolism of Ticagrelor can be decreased when combined with Buspirone.]
[L01AB01, busulfan, The metabolism of Busulfan can be decreased when combined with Ticagrelor.]
[L01XX27, arsenic trioxide, The serum concentration of Ticagrelor can be increased when it is combined with Arsenic trioxide.]
[P01BE02, artemether, The metabolism of Ticagrelor can be decreased when combined with Artemether.]
[N02AF01, butorphanol, Butorphanol can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01GX07, azelastine, The metabolism of Ticagrelor can be decreased when combined with Azelastine.]
[L01XK03, rucaparib, The metabolism of Ticagrelor can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of adverse effects can be increased when Azithromycin is combined with Ticagrelor.]
[L01EF02, ribociclib, The metabolism of Ticagrelor can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Ticagrelor.]
[N07XX16, deutetrabenazine, The metabolism of Deutetrabenazine can be decreased when combined with Ticagrelor.]
[J01XX08, linezolid, The risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Ticagrelor.]
[J05AE09, tipranavir, The metabolism of Ticagrelor can be decreased when combined with Tipranavir.]
[H03BA03, benzylthiouracil, Benzylthiouracil may increase the anticoagulant activities of Ticagrelor.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Ticagrelor.]
[L04AB02, infliximab, The metabolism of Ticagrelor can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Ticagrelor can be increased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Ticagrelor.]
[N04BD03, safinamide, The risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Ticagrelor.]
[B01AF04, betrixaban, The serum concentration of Betrixaban can be increased when it is combined with Ticagrelor.]
[L01BC06, capecitabine, The metabolism of Capecitabine can be decreased when combined with Ticagrelor.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Ticagrelor.]
[L01EH02, neratinib, The metabolism of Neratinib can be decreased when combined with Ticagrelor.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Ticagrelor.]
[L01XH01, vorinostat, The risk or severity of bleeding can be increased when Ticagrelor is combined with Vorinostat.]
[L01EM02, copanlisib, The serum concentration of Copanlisib can be increased when it is combined with Ticagrelor.]
[L01EF03, abemaciclib, The serum concentration of Abemaciclib can be increased when it is combined with Ticagrelor.]
[C07AB07, bisoprolol, The serum concentration of Bisoprolol can be increased when it is combined with Ticagrelor.]
[J05AG03, efavirenz, The metabolism of Ticagrelor can be decreased when combined with Efavirenz.]
[J01DC10, cefprozil, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Cefprozil.]
[L01BA03, raltitrexed, The risk or severity of bleeding can be increased when Ticagrelor is combined with Raltitrexed.]
[R03BA02, budesonide, The metabolism of Ticagrelor can be increased when combined with Budesonide.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Buflomedil is combined with Ticagrelor.]
[M01AB07, bumadizone, The risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Ticagrelor.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be decreased when combined with Ticagrelor.]
[J05AX18, letermovir, The metabolism of Ticagrelor can be decreased when combined with Letermovir.]
[B02BX06, emicizumab, The therapeutic efficacy of Emicizumab can be decreased when used in combination with Ticagrelor.]
[C01AA02, acetyldigoxins, The serum concentration of Acetyldigoxin can be increased when it is combined with Ticagrelor.]
[A10BK04, ertugliflozin, The serum concentration of Ertugliflozin can be increased when it is combined with Ticagrelor.]
[L02BB05, apalutamide, The metabolism of Ticagrelor can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Ticagrelor can be increased when combined with Carbamazepine.]
[H03BB01, carbimazole, Carbimazole may increase the anticoagulant activities of Ticagrelor.]
[L03AB06, interferon alfa-n1, The risk or severity of bleeding can be increased when Ticagrelor is combined with Interferon alfa-n1.]
[C07AG02, carvedilol, The serum concentration of Ticagrelor can be increased when it is combined with Carvedilol.]
[V03AB38, andexanet alfa, The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Ticagrelor.]
[N03AX24, cannabidiol, The metabolism of Ticagrelor can be decreased when combined with Cannabidiol.]
[B02BX08, avatrombopag, The serum concentration of Avatrombopag can be increased when it is combined with Ticagrelor.]
[J01DE01, cefepime, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Cefepime.]
[J01DD10, cefetamet, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Cefetamet.]
[J01DD09, cefodizime, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Cefodizime.]
[J01DC11, ceforanide, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Ceforanide.]
[J01DD13, cefpodoxime, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Cefpodoxime.]
[L01EE03, binimetinib, The serum concentration of Binimetinib can be increased when it is combined with Ticagrelor.]
[J01DD14, ceftibuten, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Ceftibuten.]
[H01CC03, elagolix, The serum concentration of Elagolix can be increased when it is combined with Ticagrelor.]
[L01XX62, ivosidenib, The metabolism of Ticagrelor can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Ticagrelor can be decreased when combined with Stiripentol.]
[B02BX07, lusutrombopag, The serum concentration of Lusutrombopag can be increased when it is combined with Ticagrelor.]
[J05AG06, doravirine, The metabolism of Doravirine can be decreased when combined with Ticagrelor.]
[L01EM04, duvelisib, The serum concentration of Duvelisib can be increased when it is combined with Ticagrelor.]
[L01EB07, dacomitinib, The serum concentration of Dacomitinib can be increased when it is combined with Ticagrelor.]
[J01AA14, sarecycline, The serum concentration of Ticagrelor can be increased when it is combined with Sarecycline.]
[J01AA15, omadacycline, The serum concentration of Omadacycline can be increased when it is combined with Ticagrelor.]
[A10BB06, carbutamide, The metabolism of Carbutamide can be decreased when combined with Ticagrelor.]
[M01AC05, lornoxicam, The risk or severity of bleeding and hemorrhage can be increased when Lornoxicam is combined with Ticagrelor.]
[L01XK04, talazoparib, The serum concentration of Talazoparib can be increased when it is combined with Ticagrelor.]
[R03BB08, revefenacin, The serum concentration of Revefenacin can be increased when it is combined with Ticagrelor.]
[L01ED05, lorlatinib, The metabolism of Lorlatinib can be decreased when combined with Ticagrelor.]
[L04AA39, emapalumab, The metabolism of Ticagrelor can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of bleeding can be increased when Ticagrelor is combined with Carmustine.]
[L01EX12, larotrectinib, The serum concentration of Larotrectinib can be increased when it is combined with Ticagrelor.]
[L01EX13, gilteritinib, The serum concentration of Gilteritinib can be increased when it is combined with Ticagrelor.]
[L01XJ03, glasdegib, The serum concentration of Glasdegib can be increased when it is combined with Ticagrelor.]
[A06AX05, prucalopride, The serum concentration of Prucalopride can be increased when it is combined with Ticagrelor.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Caplacizumab is combined with Ticagrelor.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Ticagrelor.]
[P02BX04, triclabendazole, The metabolism of Triclabendazole can be decreased when combined with Ticagrelor.]
[N06AX27, esketamine, The metabolism of Esketamine can be decreased when combined with Ticagrelor.]
[L04AA42, siponimod, The metabolism of Siponimod can be decreased when combined with Ticagrelor.]
[J01FA09, clarithromycin, The metabolism of Ticagrelor can be decreased when combined with Clarithromycin.]
[L01EN01, erdafitinib, The serum concentration of Ticagrelor can be increased when it is combined with Erdafitinib.]
[N05BA09, clobazam, The serum concentration of Clobazam can be increased when it is combined with Ticagrelor.]
[H02AB14, cloprednol, The metabolism of Ticagrelor can be increased when combined with Cloprednol.]
[C09CA06, candesartan, The metabolism of Candesartan can be decreased when combined with Ticagrelor.]
[L04AB01, etanercept, The metabolism of Ticagrelor can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The metabolism of Ticagrelor can be increased when combined with Cortivazol.]
[L01EM03, alpelisib, The metabolism of Alpelisib can be decreased when combined with Ticagrelor.]
[J01DC04, cefaclor, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Cefaclor.]
[J01DB05, cefadroxil, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Cefadroxil.]
[J01DC03, cefamandole, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Cefamandole.]
[J01DB07, cefatrizine, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Cefatrizine.]
[J01DB04, cefazolin, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Cefazolin.]
[L02BB06, darolutamide, The serum concentration of Darolutamide can be increased when it is combined with Ticagrelor.]
[J01DC09, cefmetazole, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Cefmetazole.]
[J01DC06, cefonicid, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Cefonicid.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be decreased when combined with Ticagrelor.]
[J01DD12, cefoperazone, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Cefoperazone.]
[J01DD01, cefotaxime, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Cefotaxime.]
[J01DC05, cefotetan, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Cefotetan.]
[J01DC07, cefotiam, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Cefotiam.]
[J01DC01, cefoxitin, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Cefoxitin.]
[J01DD03, cefsulodin, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Cefsulodin.]
[J01DD02, ceftazidime, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Ceftazidime.]
[J01DD07, ceftizoxime, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Ceftizoxime.]
[J01DD04, ceftriaxone, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Ceftriaxone.]
[S01AA27, cefuroxime, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Cefuroxime.]
[L01EJ02, fedratinib, The serum concentration of Fedratinib can be increased when it is combined with Ticagrelor.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be decreased when combined with Ticagrelor.]
[N07XX11, pitolisant, The serum concentration of Ticagrelor can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Pretomanid can be decreased when combined with Ticagrelor.]
[J01XX12, lefamulin, Ticagrelor may decrease the excretion rate of Lefamulin which could result in a higher serum level.]
[N04CX01, istradefylline, The serum concentration of Ticagrelor can be increased when it is combined with Istradefylline.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Cyclothiazide.]
[J01XX09, daptomycin, The serum concentration of Daptomycin can be increased when it is combined with Ticagrelor.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be decreased when combined with Ticagrelor.]
[J01DB02, cephaloridine, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Cefaloridine.]
[J01DB03, cephalothin, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Cefalotin.]
[J01DB08, cephapirin, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Cefapirin.]
[J01DB09, cephradine, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Cefradine.]
[G03DB05, demegestone, The risk or severity of adverse effects can be increased when Demegestone is combined with Ticagrelor.]
[L01FD03, ado-trastuzumab emtansine, The serum concentration of Trastuzumab emtansine can be increased when it is combined with Ticagrelor.]
[N02CC08, lasmiditan, The serum concentration of Ticagrelor can be increased when it is combined with Lasmiditan.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Ticagrelor.]
[G03AC09, desogestrel, The risk or severity of adverse effects can be increased when Desogestrel is combined with Ticagrelor.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be increased when it is combined with Ticagrelor.]
[N03AX25, cenobamate, The serum concentration of Ticagrelor can be decreased when it is combined with Cenobamate.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Ticagrelor.]
[L01FX13, enfortumab vedotin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Ticagrelor.]
[N02AX03, dezocine, Dezocine can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01EX18, avapritinib, The metabolism of Avapritinib can be decreased when combined with Ticagrelor.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be increased when it is combined with Ticagrelor.]
[L01XX72, tazemetostat, The serum concentration of Tazemetostat can be increased when it is combined with Ticagrelor.]
[N02CD06, rimegepant, The serum concentration of Rimegepant can be increased when it is combined with Ticagrelor.]
[H02CA02, osilodrostat, The metabolism of Ticagrelor can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Ticagrelor can be decreased when combined with Amprenavir.]
[G04CB02, dutasteride, The metabolism of Ticagrelor can be decreased when combined with Dutasteride.]
[L01EE04, selumetinib, The serum concentration of Selumetinib can be increased when it is combined with Ticagrelor.]
[G03DB08, dienogest, The risk or severity of adverse effects can be increased when Dienogest is combined with Ticagrelor.]
[N02AA08, dihydrocodeine, Dihydrocodeine can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N02CC06, eletriptan, The metabolism of Eletriptan can be decreased when combined with Ticagrelor.]
[M01AH02, rofecoxib, The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Ticagrelor.]
[L01XF03, bexarotene, The risk or severity of bleeding can be increased when Ticagrelor is combined with Bexarotene.]
[C01BD07, dronedarone, The metabolism of Dronedarone can be decreased when combined with Ticagrelor.]
[L01AA02, chlorambucil, The risk or severity of bleeding can be increased when Ticagrelor is combined with Chlorambucil.]
[S03AA08, chloramphenicol, The metabolism of Ticagrelor can be decreased when combined with Chloramphenicol.]
[L01EH03, tucatinib, Tucatinib may decrease the excretion rate of Ticagrelor which could result in a higher serum level.]
[L01EX17, capmatinib, The serum concentration of Ticagrelor can be increased when it is combined with Capmatinib.]
[D07XB03, fluprednidene, The metabolism of Ticagrelor can be increased when combined with Fluprednidene.]
[M01AC04, droxicam, The risk or severity of bleeding and hemorrhage can be increased when Droxicam is combined with Ticagrelor.]
[L01EX19, ripretinib, The serum concentration of Ripretinib can be increased when it is combined with Ticagrelor.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Ticagrelor is combined with Lepirudin.]
[M02AA27, dexketoprofen, The risk or severity of bleeding and hemorrhage can be increased when Dexketoprofen is combined with Ticagrelor.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Ticagrelor.]
[R06AX22, ebastine, The metabolism of Ebastine can be decreased when combined with Ticagrelor.]
[J05AX29, fostemsavir, The serum concentration of Fostemsavir can be increased when it is combined with Ticagrelor.]
[P01BB01, proguanil, The metabolism of Proguanil can be decreased when combined with Ticagrelor.]
[L01FX15, belantamab mafodotin, The serum concentration of Belantamab mafodotin can be increased when it is combined with Ticagrelor.]
[L04AC19, satralizumab, The serum concentration of Ticagrelor can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, Oliceridine can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[P01BA01, chloroquine, The metabolism of Ticagrelor can be decreased when combined with Chloroquine.]
[L01EX23, pralsetinib, The serum concentration of Pralsetinib can be increased when it is combined with Ticagrelor.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Chlorothiazide.]
[G03CA06, chlorotrianisene, Chlorotrianisene may decrease the anticoagulant activities of Ticagrelor.]
[R06AB04, chlorpheniramine, The metabolism of Ticagrelor can be decreased when combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The metabolism of Chlorpromazine can be decreased when combined with Ticagrelor.]
[A10BB02, chlorpropamide, The metabolism of Chlorpropamide can be decreased when combined with Ticagrelor.]
[N02BA07, ethenzamide, The risk or severity of bleeding and hemorrhage can be increased when Ethenzamide is combined with Ticagrelor.]
[N02BA03, choline salicylate, The risk or severity of bleeding can be increased when Choline salicylate is combined with Ticagrelor.]
[G03DC06, ethynodiol, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Etynodiol.]
[M01AB08, etodolac, The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Ticagrelor.]
[M02AA06, etofenamate, The risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Ticagrelor.]
[B06AC06, berotralstat, The serum concentration of Berotralstat can be increased when it is combined with Ticagrelor.]
[A16AX20, lonafarnib, The metabolism of Ticagrelor can be decreased when combined with Lonafarnib.]
[L01BB05, fludarabine, The risk or severity of bleeding can be increased when Ticagrelor is combined with Fludarabine.]
[L02BX04, relugolix, The serum concentration of Relugolix can be increased when it is combined with Ticagrelor.]
[L04AD03, voclosporin, The serum concentration of Voclosporin can be increased when it is combined with Ticagrelor.]
[P03AX07, abametapir, The serum concentration of Ticagrelor can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The serum concentration of Tepotinib can be increased when it is combined with Ticagrelor.]
[L01EX25, umbralisib, The serum concentration of Ticagrelor can be increased when it is combined with Umbralisib.]
[V03AF12, trilaciclib, The serum concentration of Trilaciclib can be increased when it is combined with Ticagrelor.]
[M01AE05, fenbufen, The risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Ticagrelor.]
[G04CB01, finasteride, The metabolism of Ticagrelor can be decreased when combined with Finasteride.]
[J01DD08, cefixime, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Cefixime.]
[J01DD15, cefdinir, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Cefdinir.]
[R03CC15, formoterol, The metabolism of Formoterol can be decreased when combined with Ticagrelor.]
[L04AA50, ponesimod, The metabolism of Ponesimod can be decreased when combined with Ticagrelor.]
[L01EK03, tivozanib, The serum concentration of Tivozanib can be increased when it is combined with Ticagrelor.]
[L03AB10, peginterferon alfa-2b, The risk or severity of bleeding can be increased when Ticagrelor is combined with Peginterferon alfa-2b.]
[L01FX22, loncastuximab tesirine, The serum concentration of Loncastuximab tesirine can be increased when it is combined with Ticagrelor.]
[A02BA01, cimetidine, The metabolism of Ticagrelor can be decreased when combined with Cimetidine.]
[N07CA02, cinnarizine, The metabolism of Cinnarizine can be decreased when combined with Ticagrelor.]
[L01XX73, sotorasib, The serum concentration of Ticagrelor can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be decreased when combined with Ticagrelor.]
[S03AA07, ciprofloxacin, The metabolism of Ticagrelor can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, The risk or severity of bleeding can be increased when Ticagrelor is combined with Cisplatin.]
[N06AB04, citalopram, The risk or severity of hemorrhage can be increased when Citalopram is combined with Ticagrelor.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Ticagrelor.]
[L04AA48, belumosudil, The serum concentration of Ticagrelor can be increased when it is combined with Belumosudil.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be decreased when combined with Ticagrelor.]
[L01EB10, mobocertinib, The metabolism of Mobocertinib can be decreased when combined with Ticagrelor.]
[V09GA01, technetium Tc 99m sestamibi, The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Ticagrelor.]
[M01AG01, mefenamic acid, The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Ticagrelor.]
[A10BB12, glimepiride, The metabolism of Glimepiride can be decreased when combined with Ticagrelor.]
[A10BB08, gliquidone, The metabolism of Gliquidone can be decreased when combined with Ticagrelor.]
[J01FF01, clindamycin, The metabolism of Ticagrelor can be decreased when combined with Clindamycin.]
[N06AX25, St. John's wort extract, The metabolism of Ticagrelor can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Ticagrelor can be increased when it is combined with Asciminib.]
[J05AX10, maribavir, The serum concentration of Ticagrelor can be increased when it is combined with Maribavir.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of bleeding can be increased when Ticagrelor is combined with Ropeginterferon alfa-2b.]
[D11AH08, abrocitinib, The risk or severity of bleeding and thrombocytopenia can be increased when Ticagrelor is combined with Abrocitinib.]
[J04BA01, clofazimine, The serum concentration of Ticagrelor can be increased when it is combined with Clofazimine.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Ticagrelor is combined with Tenecteplase.]
[B06AX04, mitapivat, The serum concentration of Ticagrelor can be increased when it is combined with Mitapivat.]
[L01EJ03, pacritinib, The serum concentration of Ticagrelor can be increased when it is combined with Pacritinib.]
[G03GB02, clomiphene, The serum concentration of Clomifene can be increased when it is combined with Ticagrelor.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Ticagrelor.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Ticagrelor.]
[C01EB24, mavacamten, The serum concentration of Ticagrelor can be decreased when it is combined with Mavacamten.]
[A02BC08, vonoprazan, The metabolism of Vonoprazan can be decreased when combined with Ticagrelor.]
[A04AA01, ondansetron, The metabolism of Ticagrelor can be decreased when combined with Ondansetron.]
[L01XX77, adagrasib, The serum concentration of Ticagrelor can be increased when it is combined with Adagrasib.]
[N05AH02, clozapine, The metabolism of Ticagrelor can be decreased when combined with Clozapine.]
[L01EN04, futibatinib, The serum concentration of Futibatinib can be increased when it is combined with Ticagrelor.]
[A10BK06, sotagliflozin, The serum concentration of Ticagrelor can be increased when it is combined with Sotagliflozin.]
[H01AC08, somatrogon, The metabolism of Ticagrelor can be increased when combined with Somatrogon.]
[L04AC21, bimekizumab, The metabolism of Ticagrelor can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of bleeding and hemorrhage can be increased when Proquazone is combined with Ticagrelor.]
[R05DA04, codeine, Codeine can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M04AC01, colchicine, The serum concentration of Colchicine can be increased when it is combined with Ticagrelor.]
[L01XX40, omacetaxine mepesuccinate, The risk or severity of bleeding can be increased when Ticagrelor is combined with Omacetaxine mepesuccinate.]
[J01DE02, cefpirome, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Cefpirome.]
[L04AA13, leflunomide, The metabolism of Leflunomide can be decreased when combined with Ticagrelor.]
[A10BX03, nateglinide, The metabolism of Ticagrelor can be decreased when combined with Nateglinide.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of bleeding and hemorrhage can be increased when Imidazole salicylate is combined with Ticagrelor.]
[L01BB07, nelarabine, The risk or severity of bleeding can be increased when Ticagrelor is combined with Nelarabine.]
[J01FA15, telithromycin, The metabolism of Ticagrelor can be decreased when combined with Telithromycin.]
[B01AC10, indobufen, The risk or severity of bleeding and hemorrhage can be increased when Indobufen is combined with Ticagrelor.]
[M01AH03, valdecoxib, The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Ticagrelor.]
[M01AH04, parecoxib, The risk or severity of bleeding and hemorrhage can be increased when Parecoxib is combined with Ticagrelor.]
[J02AC02, itraconazole, The metabolism of Ticagrelor can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of bleeding can be increased when Ticagrelor is combined with Bemiparin.]
[M01AA06, kebuzone, The risk or severity of bleeding and hemorrhage can be increased when Kebuzone is combined with Ticagrelor.]
[L01EA01, imatinib, The metabolism of Ticagrelor can be decreased when combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Ticagrelor can be decreased when combined with Posaconazole.]
[S01BA03, cortisone, The metabolism of Ticagrelor can be increased when combined with Cortisone.]
[M01AB09, lonazolac, The risk or severity of bleeding and hemorrhage can be increased when Lonazolac is combined with Ticagrelor.]
[M02AA31, loxoprofen, The risk or severity of bleeding and hemorrhage can be increased when Loxoprofen is combined with Ticagrelor.]
[J01DC08, loracarbef, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Loracarbef.]
[H02AB15, meprednisone, The metabolism of Ticagrelor can be increased when combined with Meprednisone.]
[C03DA04, eplerenone, The metabolism of Ticagrelor can be decreased when combined with Eplerenone.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Cyclopenthiazide.]
[J05AF07, tenofovir disoproxil, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Ticagrelor.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Ticagrelor.]
[N06AX07, minaprine, The risk or severity of bleeding and hemorrhage can be increased when Minaprine is combined with Ticagrelor.]
[S01XA18, cyclosporine, The serum concentration of Ticagrelor can be increased when it is combined with Cyclosporine.]
[N06AG02, moclobemide, The risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Ticagrelor.]
[N06BA07, modafinil, The metabolism of Ticagrelor can be increased when combined with Modafinil.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be decreased when combined with Ticagrelor.]
[M02AA02, mofebutazone, The risk or severity of bleeding and hemorrhage can be increased when Mofebutazone is combined with Ticagrelor.]
[M01AX22, morniflumate, The risk or severity of bleeding and hemorrhage can be increased when Morniflumate is combined with Ticagrelor.]
[C03XA02, conivaptan, The metabolism of Ticagrelor can be decreased when combined with Conivaptan.]
[L01BC01, cytarabine, The risk or severity of bleeding can be increased when Ticagrelor is combined with Cytarabine.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Ticagrelor.]
[M01AH05, etoricoxib, The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Ticagrelor.]
[L01AX04, dacarbazine, The risk or severity of bleeding can be increased when Ticagrelor is combined with Dacarbazine.]
[L01DA01, dactinomycin, The serum concentration of Dactinomycin can be increased when it is combined with Ticagrelor.]
[G03XA01, danazol, The metabolism of Ticagrelor can be decreased when combined with Danazol.]
[J04BA02, dapsone, The metabolism of Ticagrelor can be decreased when combined with Dapsone.]
[L01DB02, daunorubicin, The metabolism of Ticagrelor can be increased when combined with Daunorubicin.]
[A04AD11, nabilone, The metabolism of Nabilone can be decreased when combined with Ticagrelor.]
[M01AX01, nabumetone, The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Ticagrelor.]
[B02BD03, anti-inhibitor coagulant complex, The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Ticagrelor.]
[N06AX06, nefazodone, The metabolism of Ticagrelor can be decreased when combined with Nefazodone.]
[G03DB04, nomegestrol, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Nomegestrol.]
[R05DA06, normethadone, Normethadone can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B01AX05, fondaparinux, The risk or severity of bleeding can be increased when Ticagrelor is combined with Fondaparinux.]
[N06AB10, escitalopram, The risk or severity of bleeding can be increased when Escitalopram is combined with Ticagrelor.]
[A07EC03, olsalazine, The risk or severity of bleeding and hemorrhage can be increased when Olsalazine is combined with Ticagrelor.]
[L01XA03, oxaliplatin, The risk or severity of bleeding can be increased when Ticagrelor is combined with Oxaliplatin.]
[M01AE12, oxaprozin, The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Ticagrelor.]
[N03AF02, oxcarbazepine, The metabolism of Ticagrelor can be increased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The metabolism of Ticagrelor can be increased when combined with Dexamethasone.]
[G04BD04, oxybutynin, The metabolism of Ticagrelor can be decreased when combined with Oxybutynin.]
[L04AB04, adalimumab, The metabolism of Ticagrelor can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Ticagrelor can be decreased when combined with Gefitinib.]
[R05DA09, dextromethorphan, The metabolism of Ticagrelor can be decreased when combined with Dextromethorphan.]
[N03AC01, paramethadione, The metabolism of Paramethadione can be decreased when combined with Ticagrelor.]
[N02AC01, dextromoramide, Dextromoramide can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N06AB05, paroxetine, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Ticagrelor.]
[B01AC04, clopidogrel, The risk or severity of bleeding can be increased when Clopidogrel is combined with Ticagrelor.]
[N07BC06, heroin, Diamorphine can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05BA01, diazepam, The metabolism of Ticagrelor can be decreased when combined with Diazepam.]
[S01BC03, diclofenac, The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Ticagrelor.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be decreased when combined with Ticagrelor.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Ticagrelor.]
[L02AA01, diethylstilbestrol, Diethylstilbestrol may decrease the anticoagulant activities of Ticagrelor.]
[C08CA03, isradipine, The metabolism of Ticagrelor can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The metabolism of Ticagrelor can be increased when combined with Difluocortolone.]
[N02BA11, diflunisal, The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Ticagrelor.]
[C01AA04, digitoxin, The serum concentration of Digitoxin can be increased when it is combined with Ticagrelor.]
[C01AA05, digoxin, The serum concentration of Digoxin can be increased when it is combined with Ticagrelor.]
[L02AA02, polyestradiol phosphate, Polyestradiol phosphate may decrease the anticoagulant activities of Ticagrelor.]
[C04AE04, dihydroergocristine, The metabolism of Dihydroergocristine can be decreased when combined with Ticagrelor.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be decreased when combined with Ticagrelor.]
[N02AA03, hydromorphone, Hydromorphone can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AX04, lenalidomide, The risk or severity of bleeding can be increased when Ticagrelor is combined with Lenalidomide.]
[J05AE08, atazanavir, The metabolism of Ticagrelor can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, Treprostinil may increase the antiplatelet activities of Ticagrelor.]
[H03BC01, potassium perchlorate, Potassium perchlorate may increase the anticoagulant activities of Ticagrelor.]
[C08DB01, diltiazem, The metabolism of Ticagrelor can be decreased when combined with Diltiazem.]
[N02BB04, propyphenazone, The risk or severity of bleeding and hemorrhage can be increased when Propyphenazone is combined with Ticagrelor.]
[M01AB14, proglumetacin, The risk or severity of bleeding and hemorrhage can be increased when Proglumetacin is combined with Ticagrelor.]
[C05CA03, diosmin, The serum concentration of Ticagrelor can be increased when it is combined with Diosmin.]
[R06AA02, diphenhydramine, The metabolism of Diphenhydramine can be decreased when combined with Ticagrelor.]
[A07DA01, diphenoxylate, Diphenoxylate can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05CD10, quazepam, The metabolism of Quazepam can be decreased when combined with Ticagrelor.]
[B01AC07, dipyridamole, The risk or severity of bleeding can be increased when Dipyridamole is combined with Ticagrelor.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Ticagrelor is combined with Drotrecogin alfa.]
[A03FA02, cisapride, The metabolism of Cisapride can be decreased when combined with Ticagrelor.]
[S01XA23, sirolimus, The serum concentration of Sirolimus can be increased when it is combined with Ticagrelor.]
[P03AA04, disulfiram, The metabolism of Ticagrelor can be decreased when combined with Disulfiram.]
[S02AA12, rifamycin SV, The metabolism of Ticagrelor can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Ticagrelor can be increased when combined with Rifapentine.]
[D06AX11, rifaximin, The serum concentration of Rifaximin can be increased when it is combined with Ticagrelor.]
[N05AX08, risperidone, The metabolism of Ticagrelor can be decreased when combined with Risperidone.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be decreased when combined with Ticagrelor.]
[A04AD12, aprepitant, The metabolism of Ticagrelor can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The serum concentration of Tolvaptan can be increased when it is combined with Ticagrelor.]
[L01XG01, bortezomib, The serum concentration of Bortezomib can be increased when it is combined with Ticagrelor.]
[G04BE08, tadalafil, The metabolism of Ticagrelor can be decreased when combined with Tadalafil.]
[S01BC05, ketorolac, The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Ticagrelor.]
[C02KX02, ambrisentan, The serum concentration of Ambrisentan can be increased when it is combined with Ticagrelor.]
[C01EB18, ranolazine, The serum concentration of Ranolazine can be increased when it is combined with Ticagrelor.]
[N02BA06, salsalate, The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Ticagrelor.]
[R03AC12, salmeterol, The metabolism of Ticagrelor can be decreased when combined with Salmeterol.]
[A03FA03, domperidone, The metabolism of Ticagrelor can be decreased when combined with Domperidone.]
[N06AA12, doxepin, The metabolism of Doxepin can be decreased when combined with Ticagrelor.]
[L01DB01, doxorubicin, The serum concentration of Doxorubicin can be increased when it is combined with Ticagrelor.]
[J01AA02, doxycycline, The risk or severity of bleeding can be increased when Doxycycline is combined with Ticagrelor.]
[N06AB06, sertraline, The risk or severity of bleeding can be increased when Sertraline is combined with Ticagrelor.]
[A08AA10, sibutramine, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Ticagrelor.]
[C10AA01, simvastatin, The serum concentration of Simvastatin can be increased when it is combined with Ticagrelor.]
[G03DB01, dydrogesterone, Dydrogesterone may decrease the anticoagulant activities of Ticagrelor.]
[G01AF05, econazole, The metabolism of Ticagrelor can be decreased when combined with Econazole.]
[C07AB13, talinolol, The serum concentration of Talinolol can be increased when it is combined with Ticagrelor.]
[J01CG02, tazobactam, The risk or severity of bleeding can be increased when Tazobactam is combined with Ticagrelor.]
[L01AX03, temozolomide, The risk or severity of bleeding can be increased when Ticagrelor is combined with Temozolomide.]
[M01AC02, tenoxicam, The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Ticagrelor.]
[D01BA02, terbinafine, The metabolism of Terbinafine can be decreased when combined with Ticagrelor.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be decreased when combined with Ticagrelor.]
[G03CX01, tibolone, Tibolone may increase the anticoagulant activities of Ticagrelor.]
[M01AG02, tolfenamic acid, The risk or severity of bleeding and hemorrhage can be increased when Tolfenamic acid is combined with Ticagrelor.]
[N06AG03, toloxatone, The risk or severity of bleeding and hemorrhage can be increased when Toloxatone is combined with Ticagrelor.]
[L02BA02, toremifene, The risk or severity of bleeding can be increased when Toremifene is combined with Ticagrelor.]
[C03CA04, torsemide, The metabolism of Torasemide can be decreased when combined with Ticagrelor.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Triflusal is combined with Ticagrelor.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Ticagrelor is combined with Troxerutin.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be decreased when combined with Ticagrelor.]
[N06AX16, venlafaxine, The risk or severity of bleeding can be increased when Ticagrelor is combined with Venlafaxine.]
[C08CA12, mepirodipine, The metabolism of Ticagrelor can be decreased when combined with Barnidipine.]
[L01DB03, epirubicin, The risk or severity of bleeding can be increased when Ticagrelor is combined with Epirubicin.]
[N05CF02, zolpidem, The metabolism of Zolpidem can be decreased when combined with Ticagrelor.]
[M01AB04, zomepirac, The risk or severity of bleeding and hemorrhage can be increased when Zomepirac is combined with Ticagrelor.]
[N03AX15, zonisamide, The serum concentration of Ticagrelor can be increased when it is combined with Zonisamide.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Ticagrelor.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Ticagrelor is combined with Anistreplase.]
[L01XA02, carboplatin, The risk or severity of bleeding can be increased when Ticagrelor is combined with Carboplatin.]
[B01AC11, iloprost, The risk or severity of bleeding can be increased when Iloprost is combined with Ticagrelor.]
[N02CA02, ergotamine, The metabolism of Ticagrelor can be decreased when combined with Ergotamine.]
[S01AA17, erythromycin, The risk or severity of bleeding can be increased when Erythromycin is combined with Ticagrelor.]
[G03CA03, estradiol, The risk or severity of adverse effects can be increased when Estradiol is combined with Ticagrelor.]
[G03CC06, estriol, Estriol may decrease the anticoagulant activities of Ticagrelor.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the anticoagulant activities of Ticagrelor.]
[R03BA09, fluticasone furoate, The metabolism of Ticagrelor can be decreased when combined with Fluticasone furoate.]
[R03BA05, fluticasone, The metabolism of Ticagrelor can be decreased when combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Ticagrelor can be decreased when combined with Fluvastatin.]
[L02AA03, ethinyl estradiol, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Ticagrelor.]
[M01AC06, meloxicam, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Ticagrelor.]
[S01XA06, ethylmorphine, Ethylmorphine can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01CB01, etoposide, The serum concentration of Etoposide can be increased when it is combined with Ticagrelor.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Ticagrelor.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Ticagrelor.]
[R06AX12, terfenadine, The metabolism of Ticagrelor can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, The metabolism of Bupropion can be decreased when combined with Ticagrelor.]
[N06AB08, fluvoxamine, The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Ticagrelor.]
[C10AA03, pravastatin, The serum concentration of Pravastatin can be increased when it is combined with Ticagrelor.]
[B02BD08, factor VIIa, The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Ticagrelor.]
[B02BD14, antihemophilic factor, porcine B-domain truncated recombinant, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Ticagrelor.]
[A05AA01, chenodeoxycholic acid, The risk or severity of adverse effects can be increased when Ticagrelor is combined with Chenodeoxycholic acid.]
[D11AX24, deoxycholic acid, The risk or severity of adverse effects can be increased when Ticagrelor is combined with Deoxycholic acid.]
[B05AA05, dextran, The risk or severity of bleeding can be increased when Ticagrelor is combined with Dextran.]
[B02BD11, coagulation factor XIII a-subunit (recombinant), The therapeutic efficacy of Catridecacog can be decreased when used in combination with Ticagrelor.]
[B02BD07, factor XIII, The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Ticagrelor.]
[V03AF02, dexrazoxane, The risk or severity of bleeding can be increased when Ticagrelor is combined with Dexrazoxane.]
[A16AA01, levocarnitine, The therapeutic efficacy of Ticagrelor can be increased when used in combination with Levocarnitine.]
[P02CA03, albendazole, The metabolism of Albendazole can be decreased when combined with Ticagrelor.]
[C08CA02, felodipine, The metabolism of Ticagrelor can be decreased when combined with Felodipine.]
[M01AE04, fenoprofen, The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Ticagrelor.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Ticagrelor.]
[B02BB01, fibrinogen, human, The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Ticagrelor.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Ticagrelor is combined with Fibrinolysin.]
[L01BB06, clofarabine, The risk or severity of bleeding can be increased when Ticagrelor is combined with Clofarabine.]
[L04AA40, cladribine, The risk or severity of bleeding can be increased when Ticagrelor is combined with Cladribine.]
[N02BG04, floctafenine, The risk or severity of bleeding and hemorrhage can be increased when Floctafenine is combined with Ticagrelor.]
[J02AC01, fluconazole, The metabolism of Ticagrelor can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, The risk or severity of bleeding can be increased when Ticagrelor is combined with Flucytosine.]
[N07CA03, flunarizine, The metabolism of Flunarizine can be decreased when combined with Ticagrelor.]
[N05CD03, flunitrazepam, The metabolism of Flunitrazepam can be decreased when combined with Ticagrelor.]
[D07AC08, fluocinonide, The metabolism of Ticagrelor can be increased when combined with Fluocinonide.]
[H02AB03, fluocortolone, The metabolism of Ticagrelor can be increased when combined with Fluocortolone.]
[L01BC09, floxuridine, The risk or severity of bleeding can be increased when Ticagrelor is combined with Floxuridine.]
[L01BC02, fluorouracil, The risk or severity of bleeding can be increased when Ticagrelor is combined with Fluorouracil.]
[N06AB03, fluoxetine, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Ticagrelor.]
[S01BC04, flurbiprofen, The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Ticagrelor.]
[L02BB01, flutamide, The metabolism of Ticagrelor can be decreased when combined with Flutamide.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Ticagrelor.]
[G01AX06, furazolidone, The risk or severity of bleeding and hemorrhage can be increased when Furazolidone is combined with Ticagrelor.]
[J05AE10, darunavir, The metabolism of Ticagrelor can be decreased when combined with Darunavir.]
[N05CF04, eszopiclone, The metabolism of Eszopiclone can be decreased when combined with Ticagrelor.]
[L01EA02, dasatinib, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Ticagrelor.]
[N04BC06, cabergoline, The serum concentration of Cabergoline can be increased when it is combined with Ticagrelor.]
[J05AG04, etravirine, The metabolism of Etravirine can be decreased when combined with Ticagrelor.]
[G03XA02, gestrinone, The risk or severity of adverse effects can be increased when Gestrinone is combined with Ticagrelor.]
[L02AB03, gestronol, Gestonorone may decrease the anticoagulant activities of Ticagrelor.]
[N01AH02, alfentanil, Alfentanil can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01EH01, lapatinib, The serum concentration of Ticagrelor can be increased when it is combined with Lapatinib.]
[A10BB01, glyburide, The metabolism of Ticagrelor can be decreased when combined with Glyburide.]
[A10BB09, gliclazide, The metabolism of Gliclazide can be decreased when combined with Ticagrelor.]
[A10BB07, glipizide, The metabolism of Glipizide can be decreased when combined with Ticagrelor.]
[M01AX05, glucosamine, Glucosamine may increase the antiplatelet activities of Ticagrelor.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be decreased when combined with Ticagrelor.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Ticagrelor.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Ticagrelor.]
[B01AA12, fluindione, The risk or severity of bleeding can be increased when Ticagrelor is combined with Fluindione.]
[P01BX01, halofantrine, The metabolism of Ticagrelor can be decreased when combined with Halofantrine.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Ticagrelor.]
[N01AB01, halothane, The metabolism of Halothane can be decreased when combined with Ticagrelor.]
[N05AH04, quetiapine, The metabolism of Ticagrelor can be decreased when combined with Quetiapine.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be decreased when combined with Ticagrelor.]
[B06AB01, hemin, Hemin may increase the anticoagulant activities of Ticagrelor.]
[C09CA01, losartan, The metabolism of Losartan can be decreased when combined with Ticagrelor.]
[S01XA14, heparin, The risk or severity of bleeding can be increased when Ticagrelor is combined with Heparin.]
[G03DC01, allylestrenol, Allylestrenol may decrease the anticoagulant activities of Ticagrelor.]
[A07EC02, mesalamine, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Ticagrelor.]
[L01XX03, altretamine, The risk or severity of bleeding can be increased when Ticagrelor is combined with Altretamine.]
[N05CA16, hexobarbital, The metabolism of Hexobarbital can be decreased when combined with Ticagrelor.]
[J05AG01, nevirapine, The metabolism of Ticagrelor can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The metabolism of Ticagrelor can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Ticagrelor.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Hydrochlorothiazide.]
[R05DA03, hydrocodone, Hydrocodone can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S02BA01, hydrocortisone, The metabolism of Ticagrelor can be decreased when combined with Hydrocortisone.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Hydroflumethiazide.]
[G03DA03, 17-alpha-hydroxyprogesterone, Hydroxyprogesterone may decrease the anticoagulant activities of Ticagrelor.]
[L01XX05, hydroxyurea, The risk or severity of bleeding can be increased when Ticagrelor is combined with Hydroxyurea.]
[N05BB01, hydroxyzine, The metabolism of Ticagrelor can be decreased when combined with Hydroxyzine.]
[S01BA13, rimexolone, The metabolism of Ticagrelor can be increased when combined with Rimexolone.]
[R02AX02, ibuprofen, The risk or severity of bleeding can be increased when Ibuprofen is combined with Ticagrelor.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Ticagrelor is combined with Sodium citrate.]
[L01DB06, idarubicin, The risk or severity of bleeding can be increased when Ticagrelor is combined with Idarubicin.]
[L01AA06, ifosfamide, The risk or severity of bleeding can be increased when Ifosfamide is combined with Ticagrelor.]
[N01AH03, sufentanil, Sufentanil can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N06AA02, imipramine, The serum concentration of Imipramine can be increased when it is combined with Ticagrelor.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Ticagrelor.]
[L01CE01, topotecan, The serum concentration of Topotecan can be increased when it is combined with Ticagrelor.]
[S01BC01, indomethacin, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Ticagrelor.]
[L03AB04, interferon alfa-2a, The risk or severity of bleeding can be increased when Ticagrelor is combined with Interferon alfa-2a.]
[L03AB05, interferon alfa-2b, The risk or severity of bleeding can be increased when Ticagrelor is combined with Interferon alfa-2b.]
[N06AX17, milnacipran, The risk or severity of hemorrhage can be increased when Milnacipran is combined with Ticagrelor.]
[D03BA02, collagenase, The risk or severity of adverse effects can be increased when Ticagrelor is combined with Collagenase clostridium histolyticum.]
[A10BH01, sitagliptin, The serum concentration of Sitagliptin can be increased when it is combined with Ticagrelor.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Ticagrelor.]
[N05CH02, ramelteon, The metabolism of Ramelteon can be decreased when combined with Ticagrelor.]
[C10AA06, cerivastatin, The metabolism of Ticagrelor can be decreased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of bleeding can be increased when Anagrelide is combined with Ticagrelor.]
[L03AB09, interferon alfacon-1, The risk or severity of bleeding can be increased when Ticagrelor is combined with Interferon alfacon-1.]
[N06AF05, iproniazid, The risk or severity of bleeding and hemorrhage can be increased when Iproniazid is combined with Ticagrelor.]
[N06AF01, isocarboxazid, The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Ticagrelor.]
[J04AC01, isoniazid, The metabolism of Ticagrelor can be decreased when combined with Isoniazid.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Ticagrelor is combined with Bivalirudin.]
[C04AF01, kininogenase, The therapeutic efficacy of Kallidinogenase can be decreased when used in combination with Ticagrelor.]
[L04AC07, tocilizumab, The metabolism of Ticagrelor can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The metabolism of Ketamine can be decreased when combined with Ticagrelor.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Ketanserin is combined with Ticagrelor.]
[B01AC22, prasugrel, The risk or severity of bleeding can be increased when Prasugrel is combined with Ticagrelor.]
[J02AB02, ketoconazole, The metabolism of Ticagrelor can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Ticagrelor can be decreased when combined with Levoketoconazole.]
[M02AA10, ketoprofen, The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Ticagrelor.]
[V03AC03, deferasirox, The risk or severity of gastrointestinal bleeding can be increased when Ticagrelor is combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Ticagrelor can be increased when combined with Abatacept.]
[M01AE11, tiaprofenic acid, The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Ticagrelor.]
[N03AX18, lacosamide, The metabolism of Lacosamide can be decreased when combined with Ticagrelor.]
[L01DC03, mitomycin, The risk or severity of bleeding can be increased when Ticagrelor is combined with Mitomycin.]
[G03AD01, levonorgestrel, The risk or severity of adverse effects can be increased when Levonorgestrel is combined with Ticagrelor.]
[S02DA01, lidocaine, The metabolism of Ticagrelor can be decreased when combined with Lidocaine.]
[N06BA13, armodafinil, The metabolism of Ticagrelor can be increased when combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Ticagrelor.]
[L01AD02, lomustine, The risk or severity of bleeding can be increased when Ticagrelor is combined with Lomustine.]
[A07DA03, loperamide, The excretion of Loperamide can be decreased when combined with Ticagrelor.]
[C10AA02, lovastatin, The serum concentration of Lovastatin can be increased when it is combined with Ticagrelor.]
[N05AH01, loxapine, The serum concentration of Ticagrelor can be increased when it is combined with Loxapine.]
[G03DC03, lynestrenol, The risk or severity of adverse effects can be increased when Lynestrenol is combined with Ticagrelor.]
[L01EG01, temsirolimus, The serum concentration of Temsirolimus can be increased when it is combined with Ticagrelor.]
[L01EA03, nilotinib, The metabolism of Ticagrelor can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, The serum concentration of Mannitol can be increased when it is combined with Ticagrelor.]
[L01AA05, mechlorethamine, The risk or severity of bleeding can be increased when Ticagrelor is combined with Mechlorethamine.]
[M02AA18, meclofenamic acid, The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Ticagrelor.]
[C01AA08, medigoxin, The serum concentration of Metildigoxin can be increased when it is combined with Ticagrelor.]
[G03DB03, medrogestone, Medrogestone may decrease the anticoagulant activities of Ticagrelor.]
[P01BC02, mefloquine, The serum concentration of Ticagrelor can be increased when it is combined with Mefloquine.]
[B01AB06, nadroparin, The risk or severity of bleeding can be increased when Ticagrelor is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of bleeding can be increased when Ticagrelor is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of bleeding can be increased when Ticagrelor is combined with Dalteparin.]
[L01AA03, melphalan, The risk or severity of bleeding can be increased when Ticagrelor is combined with Melphalan.]
[N02AB02, meperidine, Meperidine can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N03AB04, mephenytoin, The metabolism of Mephenytoin can be decreased when combined with Ticagrelor.]
[N02AX05, meptazinol, Meptazinol can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05AX13, paliperidone, The serum concentration of Ticagrelor can be increased when it is combined with Paliperidone.]
[N07BC02, methadone, Methadone can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H03BB02, methimazole, The metabolism of Ticagrelor can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, The risk or severity of bleeding can be increased when Ticagrelor is combined with Pemetrexed.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be decreased when combined with Ticagrelor.]
[N02BG09, methoxyflurane, The metabolism of Methoxyflurane can be decreased when combined with Ticagrelor.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Methyclothiazide.]
[V04CG05, methylene blue, The serum concentration of Methylene blue can be increased when it is combined with Ticagrelor.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Ticagrelor.]
[N02CA04, methysergide, The metabolism of Methysergide can be decreased when combined with Ticagrelor.]
[P01AB01, metronidazole, The metabolism of Ticagrelor can be decreased when combined with Metronidazole.]
[S02AA13, miconazole, The metabolism of Ticagrelor can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Ticagrelor.]
[B01AB07, parnaparin, The risk or severity of bleeding can be increased when Ticagrelor is combined with Parnaparin.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Ticagrelor.]
[G03XB01, mifepristone, The risk or severity of adverse effects can be increased when Mifepristone is combined with Ticagrelor.]
[B01AB10, tinzaparin, The risk or severity of bleeding can be increased when Ticagrelor is combined with Tinzaparin.]
[C09CA03, valsartan, The metabolism of Valsartan can be decreased when combined with Ticagrelor.]
[L01XX23, mitotane, The metabolism of Ticagrelor can be increased when combined with Mitotane.]
[L01DB07, mitoxantrone, The risk or severity of bleeding can be increased when Ticagrelor is combined with Mitoxantrone.]
[L03AC01, aldesleukin, The risk or severity of bleeding can be increased when Ticagrelor is combined with Aldesleukin.]
[C01BD01, amiodarone, The metabolism of Ticagrelor can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Ticagrelor can be decreased when combined with Amitriptyline.]
[N02AA01, morphine, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Morphine.]
[J01DD06, moxalactam, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Latamoxef.]
[L04AB05, certolizumab pegol, The metabolism of Ticagrelor can be increased when combined with Certolizumab pegol.]
[L01EX03, pazopanib, The serum concentration of Pazopanib can be increased when it is combined with Ticagrelor.]
[G04CA04, silodosin, The excretion of Silodosin can be decreased when combined with Ticagrelor.]
[N03AB05, fosphenytoin, The metabolism of Ticagrelor can be increased when combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The risk or severity of bleeding can be increased when Ticagrelor is combined with Interferon beta-1b.]
[N02AF02, nalbuphine, Nalbuphine can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V03AB15, naloxone, The metabolism of Ticagrelor can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, Naltrexone can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AC03, anakinra, The metabolism of Ticagrelor can be increased when combined with Anakinra.]
[M02AA12, naproxen, The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Ticagrelor.]
[A10BG01, troglitazone, The metabolism of Ticagrelor can be decreased when combined with Troglitazone.]
[N06AX21, duloxetine, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Ticagrelor.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Ticagrelor.]
[N01AH06, remifentanil, Remifentanil can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Tirofiban is combined with Ticagrelor.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Ticagrelor.]
[N06AX23, desvenlafaxine, The risk or severity of hemorrhage can be increased when Desvenlafaxine is combined with Ticagrelor.]
[L01XX01, amsacrine, The risk or severity of bleeding can be increased when Ticagrelor is combined with Amsacrine.]
[N06AF02, nialamide, The risk or severity of bleeding and hemorrhage can be increased when Nialamide is combined with Ticagrelor.]
[C08CA04, nicardipine, The metabolism of Ticagrelor can be decreased when combined with Nicardipine.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be decreased when combined with Ticagrelor.]
[C08CA05, nifedipine, The metabolism of Ticagrelor can be decreased when combined with Nifedipine.]
[M02AA17, niflumic acid, The risk or severity of bleeding and hemorrhage can be increased when Niflumic acid is combined with Ticagrelor.]
[C08CA07, nisoldipine, The metabolism of Ticagrelor can be decreased when combined with Nisoldipine.]
[C08CA08, nitrendipine, The metabolism of Ticagrelor can be decreased when combined with Nitrendipine.]
[N05CF03, zaleplon, The metabolism of Ticagrelor can be decreased when combined with Zaleplon.]
[G03DC02, norethindrone, The risk or severity of adverse effects can be increased when Norethisterone is combined with Ticagrelor.]
[G03AC07, norgestrienone, The risk or severity of adverse effects can be increased when Norgestrienone is combined with Ticagrelor.]
[C02KX01, bosentan, The metabolism of Bosentan can be decreased when combined with Ticagrelor.]
[N06AA10, nortriptyline, The serum concentration of Nortriptyline can be increased when it is combined with Ticagrelor.]
[A16AX07, sapropterin, The serum concentration of Ticagrelor can be increased when it is combined with Sapropterin.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Eptifibatide is combined with Ticagrelor.]
[B01AB08, reviparin, The risk or severity of bleeding can be increased when Ticagrelor is combined with Reviparin.]
[L04AC04, rilonacept, The metabolism of Ticagrelor can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be decreased when combined with Ticagrelor.]
[N02AA02, opium, Opium can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Ticagrelor is combined with Reteplase.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Ticagrelor is combined with Ancrod.]
[N02AA05, oxycodone, Oxycodone can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N02AA11, oxymorphone, Oxymorphone can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01BC02, oxyphenbutazone, The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Ticagrelor.]
[J04AA01, aminosalicylic acid, The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Ticagrelor.]
[B01AB09, danaparoid, The risk or severity of bleeding can be increased when Ticagrelor is combined with Danaparoid.]
[N02AX06, tapentadol, Tapentadol can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G03DB06, chlormadinone, The risk or severity of adverse effects can be increased when Chlormadinone is combined with Ticagrelor.]
[H02AB05, paramethasone, The metabolism of Ticagrelor can be increased when combined with Paramethasone.]
[C02KC01, pargyline, The risk or severity of bleeding and hemorrhage can be increased when Pargyline is combined with Ticagrelor.]
[M01CC01, penicillamine, The risk or severity of bleeding can be increased when Ticagrelor is combined with Penicillamine.]
[N02AD01, pentazocine, Pentazocine can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05CA01, pentobarbital, The metabolism of Ticagrelor can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, The risk or severity of bleeding can be increased when Ticagrelor is combined with Pentostatin.]
[C04AD03, pentoxifylline, The therapeutic efficacy of Ticagrelor can be increased when used in combination with Pentoxifylline.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Ticagrelor.]
[N02AD02, phenazocine, Phenazocine can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N06AF03, phenelzine, The risk or severity of bleeding and hemorrhage can be increased when Phenelzine is combined with Ticagrelor.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Ticagrelor is combined with Phenindione.]
[N03AA02, phenobarbital, The metabolism of Ticagrelor can be increased when combined with Phenobarbital.]
[N01AH04, phenoperidine, Phenoperidine can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B01AA04, phenprocoumon, The risk or severity of bleeding can be increased when Ticagrelor is combined with Phenprocoumon.]
[M02AA01, phenylbutazone, The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Ticagrelor.]
[N03AB02, phenytoin, The metabolism of Ticagrelor can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Ticagrelor can be increased when combined with Golimumab.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be decreased when combined with Ticagrelor.]
[C08CX01, mibefradil, The serum concentration of Ticagrelor can be increased when it is combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Ticagrelor.]
[C10AA05, atorvastatin, The serum concentration of Atorvastatin can be increased when it is combined with Ticagrelor.]
[J05AE01, saquinavir, The metabolism of Ticagrelor can be decreased when combined with Saquinavir.]
[N02AC03, pirinitramide, Piritramide can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01BC06, piroxicam, The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Ticagrelor.]
[J01DD16, cefditoren, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Cefditoren.]
[J05AG02, delavirdine, The metabolism of Ticagrelor can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Irbesartan can be decreased when combined with Ticagrelor.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Abciximab is combined with Ticagrelor.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Ticagrelor is combined with Alteplase.]
[A10BG02, rosiglitazone, The metabolism of Rosiglitazone can be decreased when combined with Ticagrelor.]
[A03AE01, alosetron, The metabolism of Alosetron can be decreased when combined with Ticagrelor.]
[L04AC08, canakinumab, The metabolism of Ticagrelor can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Polythiazide.]
[J05AE03, ritonavir, The metabolism of Ticagrelor can be decreased when combined with Ritonavir.]
[A10BH03, saxagliptin, The metabolism of Ticagrelor can be decreased when combined with Saxagliptin.]
[V03AB21, potassium iodide, Potassium Iodide may increase the anticoagulant activities of Ticagrelor.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Ticagrelor.]
[P02BA01, praziquantel, The metabolism of Ticagrelor can be decreased when combined with Praziquantel.]
[P01BA03, primaquine, The metabolism of Ticagrelor can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Ticagrelor can be increased when combined with Primidone.]
[S01HA05, procaine, The risk or severity of bleeding and hemorrhage can be increased when Procaine is combined with Ticagrelor.]
[L01XB01, procarbazine, The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Ticagrelor.]
[C10AB05, fenofibrate, The metabolism of Fenofibrate can be decreased when combined with Ticagrelor.]
[G03DA04, progesterone, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Progesterone.]
[N05AA03, promazine, The metabolism of Promazine can be decreased when combined with Ticagrelor.]
[G03DB07, promegestone, Promegestone may decrease the anticoagulant activities of Ticagrelor.]
[C01BC03, propafenone, The serum concentration of Ticagrelor can be increased when it is combined with Propafenone.]
[R06AX26, fexofenadine, The serum concentration of Fexofenadine can be increased when it is combined with Ticagrelor.]
[L01XH02, romidepsin, The serum concentration of Romidepsin can be increased when it is combined with Ticagrelor.]
[N01AX10, propofol, The metabolism of Propofol can be decreased when combined with Ticagrelor.]
[N02AC04, propoxyphene, Dextropropoxyphene can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C07AA05, propranolol, The metabolism of Ticagrelor can be decreased when combined with Propranolol.]
[H03BA02, propylthiouracil, Propylthiouracil may increase the anticoagulant activities of Ticagrelor.]
[B01AC09, epoprostenol, The risk or severity of bleeding can be increased when Epoprostenol is combined with Ticagrelor.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Ticagrelor.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Ticagrelor.]
[M09AB02, collagenase Clostridium histolyticum, The risk or severity of adverse effects can be increased when Ticagrelor is combined with Collagenase clostridium histolyticum.]
[P01AX05, quinacrine, The metabolism of Ticagrelor can be decreased when combined with Quinacrine.]
[C01BA01, quinidine, The therapeutic efficacy of Ticagrelor can be increased when used in combination with Quinidine.]
[P01BC01, quinine, The therapeutic efficacy of Ticagrelor can be increased when used in combination with Quinine.]
[C02AA02, reserpine, The serum concentration of Ticagrelor can be increased when it is combined with Reserpine.]
[J04AB02, rifampin, The metabolism of Ticagrelor can be increased when combined with Rifampicin.]
[N02BA05, salicylamide, The risk or severity of bleeding and hemorrhage can be increased when Salicylamide is combined with Ticagrelor.]
[A07EC01, sulfasalazine, The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Ticagrelor.]
[S01BC08, salicylic acid, The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Ticagrelor.]
[N04BD01, selegiline, The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with Ticagrelor.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Ticagrelor is combined with Obinutuzumab.]
[L01CD04, cabazitaxel, The serum concentration of Cabazitaxel can be increased when it is combined with Ticagrelor.]
[N03AG01, valproic acid, The metabolism of Valproic acid can be decreased when combined with Ticagrelor.]
[D07AB02, hydrocortisone butyrate, The metabolism of Hydrocortisone butyrate can be decreased when combined with Ticagrelor.]
[A05AA02, ursodiol, The risk or severity of adverse effects can be increased when Ticagrelor is combined with Ursodeoxycholic acid.]
